Abbott Laboratories (ABT): Among the Best Drug Stocks to Buy Now

Abbott Laboratories (ABT) has consistently demonstrated strong performance and growth potential in the drug sector, making it an attractive investment opportunity for those seeking exposure to the pharmaceutical industry. With a diversified product portfolio and a global presence, ABT is well-positioned to navigate changing market conditions and capitalize on emerging opportunities.



ABT's diversified product portfolio spans four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. This diversification allows the company to mitigate risks associated with relying on a single product or segment. In 2024, ABT's Medical Devices segment contributed 44% of its total sales, while the other segments accounted for the remaining 56%. This balance helps the company weather fluctuations in any one segment.



ABT's geographic reach exposes the company to various economic conditions and market trends, reducing the impact of any single market downturn. In 2024, international sales accounted for 61% of ABT's total revenue. This global presence has historically enabled ABT to navigate changing market conditions and maintain consistent growth.



ABT's recent innovations and product approvals play a significant role in driving future growth and revenue streams. The company has a highly productive R&D pipeline, which has resulted in more than 15 new growth opportunities announced during 2024. These include new product approvals and new treatment indications, such as the FreeStyle Libre 3 continuous glucose monitoring system and the Trio S heart rhythm management device.

ABT's strong financial performance, including revenue growth and earnings per share growth, contributes to its growth potential in the drug sector. In 2024, the company achieved the upper end of its initial guidance ranges for both organic sales growth and adjusted earnings per share. This consistent performance demonstrates ABT's ability to deliver on its commitments and drive growth.



ABT's experienced management team, led by Chairman and CEO Robert B. Ford, has a proven track record of delivering on the company's commitments and driving growth. The team's expertise and strategic vision contribute to the company's strong performance and growth potential.

In conclusion, Abbott Laboratories (ABT) is an attractive investment opportunity for those seeking exposure to the pharmaceutical industry. With a diversified product portfolio, global presence, and a strong pipeline of recent innovations, ABT is well-positioned to navigate changing market conditions and capitalize on emerging opportunities. The company's consistent financial performance and experienced management team further support its growth potential, making it an ideal choice for investors looking to buy drug stocks now.